Skip to main content
MLYS
NASDAQ Life Sciences

Mineralys Q3 Loss Widens to $57.3M as Lorundrostat Launch Build-Out Accelerates Ahead of Dec 22 PDUFA

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$17.16
Mkt Cap
$1.503B
52W Low
$15.33
52W High
$47.65
52W Position info
12% above low
Off High info
64% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

MLYS is trading near its 52-week low of $15.33 (12% above the low).

Summary

Mineralys reported a $57.3M Q3 net loss driven by commercialization spending, with $624.7M in cash funding operations into 2028 and the lorundrostat PDUFA date set for December 22, 2026. A director also resigned effective year-end.


Key Events · Earnings and Guidance · MLYS

  • Q3 Net Loss Widens to $57.3M

    Net loss was $57.3M for the quarter ended September 30, 2026, versus $36.9M a year earlier; nine-month net loss reached $337.7M.

  • Commercial Build-Out Drives G&A Jump

    G&A expenses rose to $37.4M from $9.7M, including $15.4M of higher professional fees and $11.4M of added personnel costs ahead of launch. R&D fell to $22.7M from $31.5M as the pivotal program wound down.

  • Cash Funds Operations Into 2028

    Cash, cash equivalents and investments stood at $624.7M as of September 30, 2026, which the company says funds planned operations including the lorundrostat commercial launch into 2028.

  • PDUFA Decision Set for December 22, 2026

    The FDA continues its review of the lorundrostat NDA with a PDUFA target date of December 22, 2026; the company reports an expanded medical affairs team and sales force in place.


Analysis · MLYS · Life Sciences

The quarter's headline is the cost of getting ready to sell: G&A jumped to $37.4M from $9.7M a year ago as Mineralys staffed a sales force and medical affairs team, pushing the net loss to $57.3M from $36.9M. That spending is deliberate — the FDA decides on lorundrostat by December 22, 2026, and the company says launch prep is on track. With $624.7M in cash and a stated runway into 2028, the burn is funded, so the loss is a spending story rather than a solvency one. The supporting data readouts (46% of 50 mg patients at guideline SBP target, an 11.1 mmHg OSA reduction) keep the approval case intact. Separately, director Derek DiRocco resigned effective December 31, 2026, citing no disagreement.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MLYS was trading at $17.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $15.33 to $47.65. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MLYS - Latest Insights

MLYS
Nov 04, 2026, 5:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $16.82
Real-time Price: $14.05 info
Change: -$2.77 (-16%) info
Market Cap: $1.22B info
MLYS
Oct 29, 2026, 4:08 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $21.24
Real-time Price: $14.05 info
Change: -$7.19 (-34%) info
Market Cap: $1.22B info
MLYS
Oct 28, 2026, 7:05 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $21.30
Real-time Price: $14.05 info
Change: -$7.25 (-34%) info
Market Cap: $1.22B info
MLYS
Oct 22, 2026, 6:40 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $21.47
Real-time Price: $14.05 info
Change: -$7.42 (-35%) info
Market Cap: $1.22B info
MLYS
Oct 09, 2026, 9:00 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $22.35
Real-time Price: $14.05 info
Change: -$8.30 (-37%) info
Market Cap: $1.22B info